4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-424317
Director sold 14,514 shares at $49.63 ($720,373)
- Director acquired 30,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
George Simeon · Director
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-10-14 | Exercise or conversion : show line 1 in the form 10b5-1 | +30,000 | $14.00 | $420,000 | 30,000 | D |
| 2026-10-14 | Sale : show line 2 in the form 10b5-1 | −14,514 | $49.63 | $720,373 | 15,486 | D |
| Open-market sales · 14,514 sh · avg $49.63 · $720,373 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-10-14 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −30,000 | 0 | D |
Loading xslF345X06/ownership.xml…